ORAL FORMULATIONS MIMETIC OF ROUX-EN-Y GASTRIC BYPASS ACTIONS ON THE ILEAL BRAKE/ COMPOSITIONS, METHODS OF TREATMENT, DIAGNOSTICS AND SYSTEMS FOR TREATMENT OF METABOLIC SYNDROME MANIFESTATIONS INCLUDING INSULIN RESISTANCE, FATTY LIVER DISEASE, HYPERLIPIDEMIA, AND T2D
SCHENTAG JEROME;파야드, 조셉, 엠.;쉔타그, 제롬;FAYAD JOSEPH M.
发明人:
FAYAD JOSEPH M.,파야드, 조셉, 엠.,SCHENTAG JEROME,쉔타그, 제롬
申请号：
KR1020147014114
公开号：
KR1020140093963A
申请日:
2012.10.26
申请国别(地区):
KR
年份:
2014
代理人:
摘要：
The invention provides pharmaceutical compositions, methods for the treatment of, and related diagnostics and computer-implementable systems that relate to, the treatment of a variety of metabolic syndromes, including hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states. In an additional aspect of the invention, compositions and methods of treatment are calibrated to the ileal brake response to surgical intervention e.g. Roux-en-Y gastric bypass (RYGB)) as both activate the ileal brake, which acts in the gastrointestinal tract and the liver of a mammal to control metabolic syndrome manifestations and thereby reverse or ameliorate the cardiovascular damage (atherosclerosis, hypertension, lipid accumulation, and the like) resulting from progression of metabolic syndrome. The net benefit is the potential to treat all of the common manifestations of metabolic syndrome, including Type 2 diabetes and obesity, with one medicament, which contains glucose as an activation agent for the ileal brake. The ileal brake is the controller for progression of metabolic syndrome, and both RYGB surgery and the oral formulation act beneficially on the metabolic syndrome manifestations via this pathway. Disclosed as well are combination medicaments that act synergistically on the ileal brake and the manifestations of metabolic syndrome. In other aspects, the invention provides ileal brake hormone releasing compositions, methods of treatment, diagnostics, and related systems useful in selective control of appetite, stabilizing blood glucose and insulin levels, and treating gastrointestinal disorders in a similar manner to RYGB surgery, but having at least 20% of the potency to stimulate the hormonal response of the ileal brake of humans.본 발명은 고지혈증, 체중 증가, 비만, 인슐린 저항성, 고혈압, 죽상동맥경화증, 지방간 질환들 및 특정 만성 염증 질환들을 포함하는 다양한 대사 증후군들의 치료에 관한, 약학 조성물, 치료를 위한 방법들, 및 관련 진단과 컴퓨터로 구현가능한 시스템들을 제공한다. 본 발명의 부가적인
